

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

CHANGE OF COMPLIANCE ADVISER

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”) pursuant to Rules 3A.29 and 13.51(6) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that the compliance adviser’s agreement entered into between the Company and China Sunrise Capital Limited (“**China Sunrise Capital**”) dated 29 May 2024 has been terminated with effect from 31 August 2026 after mutual agreement between the Company and China Sunrise Capital (the “**Termination**”). The Termination was due to the resignations of various responsible officers of China Sunrise Capital effective on 31 August 2026, as a result of which China Sunrise Capital will no longer be qualified to provide compliance advisory services to an acceptable standard to the Company pursuant to Rule 3A.26 of the Listing Rules.

Save as disclosed in this announcement, each of the Board and China Sunrise Capital confirms that, as at the date of this announcement, there is no other matter relating to the Termination that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board hereby further announces that Ignite Capital (Asia Pacific) Limited (“**Ignite Capital**”) has been appointed as the new compliance adviser to the Company as required pursuant to Rule 3A.27 of the Listing Rules with effect from 31 August 2026 until the date, pursuant to Rule 3A.19 of the Listing Rules, on which the Company complies with Rule 13.46 of the Listing Rules in respect of the financial results of the Company to be published for the first full financial year commencing after the date of its initial listing (being the financial year ending 31 December 2026), or until the compliance adviser’s agreement entered into between the Company and Ignite Capital is terminated in accordance with its terms, whichever is earlier.

Ignite Capital is a licensed corporation permitted to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
31 August 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.